Towards the realization of clinical extracellular vesicle diagnostics: Challenges and opportunities

Expert Review of Molecular Diagnostics

Volumn 15, Issue 12, 2015, Pages 1555-1566

  Yokoi, Akira ^a   Yoshioka, Yusuke ^a   Ochiya, Takahiro ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

circulating miRNAs; EV associated proteins; EV associated RNAs; Extracellular vesicles; liquid biopsy

Indexed keywords

CAVEOLIN 1; CD63 ANTIGEN; CD81 ANTIGEN; CD9 ANTIGEN; CELL PROTEIN; EPITHELIAL CELL ADHESION MOLECULE; HEAT SHOCK PROTEIN 70; MEMBRANE PROTEIN; MESSENGER RNA; MICRORNA; RAB PROTEIN; RNA; SURVIVIN; TETRASPANIN; TUMOR MARKER; BIOLOGICAL MARKER;

BIOPSY; CANCER DIAGNOSIS; CANCER PATIENT; DIAGNOSTIC TEST; ENZYME LINKED IMMUNOSORBENT ASSAY; EXOSOME; EXTRACELLULAR SPACE; HUMAN; LIQUID BIOPSY; MEMBRANE MICROPARTICLE; MOLECULAR DIAGNOSIS; NONHUMAN; REVIEW; RNA ANALYSIS; ANIMAL; GENETICS; METABOLISM; NEOPLASMS;

ANIMALS; BIOMARKERS; BIOMARKERS, TUMOR; EXTRACELLULAR VESICLES; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASMS;

EID: 84949539345     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2015.1104249     Document Type: Review

References (97)

1. Zitvogel L, Angevin E, Tursz T. Dendritic cell-based immunotherapy of cancer. Ann Oncol. 2000;11 Suppl 3:199-205.
2. Johnstone RM, Bianchini A, Teng K. Reticulocyte maturation and exosome release: transferrin receptor containing exosomes shows multiple plasma membrane functions. Blood. 1989;74 (5):1844-1851.
3. Clayton A, Turkes A, Navabi H, et al. Induction of heat shock proteins in B-cell exosomes. J Cell Sci. 2005;118(Pt 16):3631-3638.
4. Skokos D, Goubran-Botros H, Roa M, et al. Immunoregulatory properties of mast cell-derived exosomes. Mol Immunol. 2002; 38 (16-18): 1359-1362.
5. Amigorena S. Anti-tumour immunotherapy using dendritic-cell-derived exosomes. Res Immunol. 1998; 149 (7-8): 661-662.
6. Heijnen HF, Schiel AE, Fijnheer R, et al. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. Blood. 1999;94 (11):3791-3799.
7. Van Niel G, Raposo G, Candalh C, et al. Intestinal epithelial cells secrete exosomelike vesicles. Gastroenterology. 2001;121 (2):337-349.
8. Faure J, Lachenal G, Court M, et al. Exosomes are released by cultured cortical neurones. Mol Cell Neurosci. 2006;31 (4):642-648.
9. Gould SJ, Raposo G. As we wait: coping with an imperfect nomenclature for extracellular vesicles. J Extracell Vesicles. 2013;2:20389.
10. Lotvall J, Hill AF, Hochberg F, et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: A position statement from the International Society for Extracellular Vesicles. J Extracell Vesicles. 2014;3:26913.
11. Bobryshev YV, Killingsworth MC, Huynh TG, et al. Are calcifying matrix vesicles in atherosclerotic lesions of cellular origin? Basic Res Cardiol. 2007;102 (2):133-143.
12. Hess C, Sadallah S, Hefti A, et al. Ectosomes released by human neutrophils are specialized functional units. J Immunol. 1999;163(8):4564-4573.
13. Utleg AG, Yi EC, Xie T, et al. Proteomic analysis of human prostasomes. Prostate. 2003;56(2):150-161.
14. Di Vizio D, Kim J, Hager MH, et al. Oncosome formation in prostate cancer: Association with a region of frequent chromosomal deletion in metastatic disease. Cancer Res. 2009;69(13):5601-5609.
15. Harding C, Heuser J, Stahl P. Receptormediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J Cell Biol. 1983;97 (2):329-339.
16. Johnstone RM, Adam M, Hammond JR, et al. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J Biol Chem. 1987;262 (19):9412-9420.
17. Théry C. Exosomes: secreted vesicles and intercellular communications. F1000 Biol Rep. 2011;3:15.
18. Johnstone RM, Mathew A, Mason AB, et al. Exosome formation during maturation of mammalian and avian reticulocytes: evidence that exosome release is a major route for externalization of obsolete membrane proteins. J Cell Physiol. 1991;147(1):27-36.
19. Johnstone RM. The Jeanne Manery-Fisher memorial lecture 1991. Maturation of reticulocytes: formation of exosomes as a mechanism for shedding membrane proteins. Biochem Cell Biol. 1992; 70 (3-4): 179-190.
20. Bobrie A, Colombo M, Raposo G, et al. Exosome secretion: molecular mechanisms and roles in immune responses. Traffic. 2011;12(12):1659-1668.
21. Van Der Pol E, Boing AN, Harrison P, et al. Classification, functions, and clinical relevance of extracellular vesicles. Pharmacol Rev. 2012;64(3):676-705.
22. Gonzalez E, Falcon-Perez JM. Cellderived extracellular vesicles as a platform to identify low-invasive disease biomarkers. Expert Rev Mol Diagn. 2015;15 (7):907-923.
23. Valadi H, Ekstrom K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654-659.
24. Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, et al. Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci USA. 2010 ;107 (14):6328-6333.
25. Zhang Y, Liu D, Chen X, et al. Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol Cell. 2010;39(1):133-144.
26. Kosaka N, Iguchi H, Yoshioka Y, et al. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem. 2010;285(23):17442-17452.
27. Pantel K, Alix-Panabieres C. Real-time liquid biopsy in cancer patients: fact or fiction? Cancer Res. 2013;73 (21):6384-6388.
28. Melo SA, Luecke LB, Kahlert C, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015;523(7559):177-182.
29. Maurya P, Meleady P, Dowling P, et al. Proteomic approaches for serum biomarker discovery in cancer. Anticancer Res. 2007;27(3A):1247-1255.
30. Pavlou MP, Diamandis EP. The cancer cell secretome: A good source for discovering biomarkers? J Proteom. 2010;73 (10):1896-1906.
31. Garnier D, Magnus N, Lee TH, et al. Cancer cells induced to express mesenchymal phenotype release exosome-like extracellular vesicles carrying tissue factor. J Biol Chem. 2012;287(52):43565-43572.
32. Bast RC Jr., Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309(15):883-887.
33. Mol BW, Bayram N, Lijmer JG, et al. The performance of CA-125 measurement in the detection of endometriosis: A meta-analysis. Fertil Steril. 1998;70 (6):1101-1108.
34. Yanez-Mo M, Siljander PR, Andreu Z, et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 2015;4:27066.
35. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008;110(1):13-21.
36. Logozzi M, De Milito A, Lugini L, et al. High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS One. 2009;4(4):e5219.
37. Lu Q, Zhang J, Allison R, et al. Identification of extracellular delta-catenin accumulation for prostate cancer detection. Prostate. 2009;69(4):411-418.
38. Rabinowits G, Gercel-Taylor C, Day JM, et al. Exosomal microRNA: A diagnostic marker for lung cancer. Clin Lung Cancer. 2009;10(1):42-46.
39. Taylor DD, Gercel-Taylor C, Parker LP. Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer. Gynecol Oncol. 2009;115(1):112-120.
40. Choi DS, Park JO, Jang SC, et al. Proteomic analysis of microvesicles derived from human colorectal cancer ascites. Proteomics. 2011;11(13):2745-2751.
41. Nilsson J, Skog J, Nordstrand A, et al. Prostate cancer-derived urine exosomes: A novel approach to biomarkers for prostate cancer. Br J Cancer. 2009;100 (10):1603-1607.
42. Tavoosidana G, Ronquist G, Darmanis S, et al. Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer. Proc Natl Acad Sci USA. 2011;108(21):8809-8814.
43. Bryant RJ, Pawlowski T, Catto JW, et al. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer. 2012;106(4):768-774.
44. Khan S, Jutzy JM, Valenzuela MM, et al. Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer. PLoS One. 2012;7(10): e46737.
45. Murakami Y, Toyoda H, Tanahashi T, et al. Comprehensive miRNA expression analysis in peripheral blood can diagnose liver disease. PLoS One. 2012;7(10): e48366.
46. Shao H, Chung J, Balaj L, et al. Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat Med. 2012;18 (12):1835-1840.
47. Noerholm M, Balaj L, Limperg T, et al. RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls. BMC Cancer. 2012;12:22.
48. Tanaka Y, Kamohara H, Kinoshita K, et al. Clinical impact of serum exosomal microRNA-21 as a clinical biomarker in human esophageal squamous cell carcinoma. Cancer. 2013;119(6):1159-1167.
49. Lau C, Kim Y, Chia D, et al. Role of pancreatic cancer-derived exosomes in salivary biomarker development. J Biol Chem. 2013;288(37):26888-26897.
50. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10(10):704-714.
51. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75 (5):843-854.
52. Rosenfeld N, Aharonov R, Meiri E, et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol. 2008;26 (4):462-469.
53. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435 (7043):834-838.
54. Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumourassociated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008;141 (5):672-675.
55. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable bloodbased markers for cancer detection. Proc Natl Acad Sci USA. 2008;105 (30):10513-10518.
56. Brase JC, Johannes M, Schlomm T, et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer. 2011;128(3):608-616.
57. El-Hefnawy T, Raja S, Kelly L, et al. Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics. Clin Chem. 2004;50(3):564-573.
58. Chen LC, Liu HP, Li HP, et al. Thymidine phosphorylase mRNA stability and protein levels are increased through ERK-mediated cytoplasmic accumulation of hnRNP K in nasopharyngeal carcinoma cells. Oncogene. 2009;28(17):1904-1915.
59. Hunter MP, Ismail N, Zhang X, et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS One. 2008;3(11):e3694.
60. Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA. 2011;108(12):5003-5008.
61. Vickers KC, Palmisano BT, Shoucri BM, et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011;13(4):423-433.
62. Takeshita N, Hoshino I, Mori M, et al. Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma. Br J Cancer. 2013;108(3):644-652.
63. Ogata-Kawata H, Izumiya M, Kurioka D, et al. Circulating exosomal microRNAs as biomarkers of colon cancer. PLoS One. 2014;9(4):e92921.
64. Went PT, Lugli A, Meier S, et al. Frequent EpCam protein expression in human carcinomas. Hum Pathol. 2004;35(1):122-128.
65. Herlyn M, Steplewski Z, Herlyn D, et al. Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci USA. 1979;76 (3):1438-1442.
66. Poczatek RB, Myers RB, Manne U, et al. Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. J Urol. 1999;162(4):1462-1466.
67. Zhang S, Zhang HS, Reuter VE, et al. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin Cancer Res. 1998;4(2):295-302.
68. Ruck P, Wichert G, Handgretinger R, et al. Ep-CAM in malignant liver tumours. J Pathol. 2000;191(1):102-103.
69. De Boer CJ, Van Krieken JH, Janssenvan Rhijn CM, et al. Expression of Ep-CAM in normal, regenerating, metaplastic, and neoplastic liver. J Pathol. 1999;188(2):201-206.
70. Sansonno D, Dammacco F. Expression and distribution of a human colon-carcinoma-associated antigen in normal and diseased liver tissue. Pathobiology. 1993; 61 (3-4): 193-196.
71. Kumble S, Omary MB, Fajardo LF, et al. Multifocal heterogeneity in villin and Ep-CAM expression in Barrett's esophagus. Int J Cancer. 1996;66(1):48-54.
72. Martin IG, Cutts SG, Birbeck K, et al. Expression of the 17-1A antigen in gastric and gastro-oesophageal junction adenocarcinomas: A potential immunotherapeutic target? J Clin Pathol. 1999;52 (9):701-704.
73. Piyathilake CJ, Frost AR, Weiss H, et al. The expression of Ep-CAM (17-1A) in squamous cell cancers of the lung. Hum Pathol. 2000;31(4):482-487.
74. Kubuschok B, Passlick B, Izbicki JR, et al. Disseminated tumor cells in lymph nodes as a determinant for survival in surgically resected non-small-cell lung cancer. J Clin Oncol. 1999;17(1):19-24.
75. Takes RP, Baatenburg De Jong RJ, Schuuring E, et al. Markers for assessment of nodal metastasis in laryngeal carcinoma. Arch Otolaryngol Head Neck Surg. 1997;123(4):412-419.
76. Szala S, Froehlich M, Scollon M, et al. Molecular cloning of cDNA for the carcinoma-associated antigen GA733-2. Proc Natl Acad Sci USA. 1990;87 (9):3542-3546.
77. Edwards DP, Grzyb KT, Dressler LG, et al. Monoclonal antibody identification and characterization of a Mr 43,000 membrane glycoprotein associated with human breast cancer. Cancer Res. 1986;46(3):1306-1317.
78. Bijnsdorp IV, Geldof AA, Lavaei M, et al. Exosomal ITGA3 interferes with noncancerous prostate cell functions and is increased in urine exosomes of metastatic prostate cancer patients. J Extracell Vesicles. 2013;2:22097.
79. Nakahara T, Kita A, Yamanaka K, et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res. 2007;67(17):8014-8021.
80. Khan S, Jutzy JM, Aspe JR, et al. Survivin is released from cancer cells via exosomes. Apoptosis Int J Program Cell Death. 2011;16(1):1-12.
81. Jorgensen M, Baek R, Pedersen S, et al. Extracellular vesicle (EV) array: microarray capturing of exosomes and other extracellular vesicles for multiplexed phenotyping. J Extracell Vesicles. 2013;2:20920.
82. Jakobsen KR, Paulsen BS, Baek R, et al. Exosomal proteins as potential diagnostic markers in advanced non-small cell lung carcinoma. J Extracell Vesicles. 2015;4:26659.
83. Shao H, Chung J, Lee K, et al. Chipbased analysis of exosomal mRNA mediating drug resistance in glioblastoma. Nat Commun. 2015;6:6999.
84. Ueda K, Ishikawa N, Tatsuguchi A, et al. Antibody-coupled monolithic silica microtips for highthroughput molecular profiling of circulating exosomes. Sci Rep. 2014;4:6232.
85. Fong MY, Zhou W, Liu L, et al. Breastcancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat Cell Biol. 2015;17(2):183-194.
86. Zhou W, Fong MY, Min Y, et al. Cancersecreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell. 2014;25(4):501-515.
87. Alvarez-Erviti L, Seow Y, Yin H, et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011;29(4):341-345.
88. Ohno S, Takanashi M, Sudo K, et al. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol Ther. 2013;21 (1):185-191.
89. Yoshioka Y, Kosaka N, Konishi Y, et al. Ultra-sensitive liquid biopsy of circulating extracellular vesicles using ExoScreen. Nat Commun. 2014;5:3591.
90. Im H, Shao H, Park YI, et al. Label-free detection and molecular profiling of exosomes with a nano-plasmonic sensor. Nat Biotechnol. 2014;32(5):490-495.
91. Zuckerman E, Lanir A, Sabo E, et al. Cancer antigen 125: A sensitive marker of ascites in patients with liver cirrhosis. Am J Gastroenterol. 1999;94(6):1613-1618.
92. Ratajczak J, Miekus K, Kucia M, et al. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia. 2006;20 (5):847-856.
93. Devarbhavi H, Kaese D, Williams AW, et al. Cancer antigen 125 in patients with chronic liver disease. Mayo Clin Proc. 2002;77(6):538-541.
94. Sjovall K, Nilsson B, Einhorn N. The significance of serum CA 125 elevation in malignant and nonmalignant diseases. Gynecol Oncol. 2002;85(1):175-178.
95. Simpson RJ, Lim JW, Moritz RL, et al. Exosomes: proteomic insights and diagnostic potential. Expert Rev Proteom. 2009;6(3):267-283.
96. Raposo G, Nijman HW, Stoorvogel W, et al. B lymphocytes secrete antigen-presenting vesicles. J Exp Med. 1996;183 (3):1161-1172.
97. Santen DR, Payne JT, Pace LW, et al. Thoracolumbar vertebral osteochondroma in a young dog. J Am Vet Med Assoc. 1991;199(8):1054-1056.